证券代码：603567 证券简称：珍宝岛 公告编号：2025-045 黑龙江珍宝岛药业股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通 过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (一) 股东大会类型和届次 2024年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 25 日 14 点 00 分 召开地点：哈尔滨市平房开发区烟台一路 8 号 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 25 日 至 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-043 黑龙江珍宝岛药业股份有限公司 第五届监事会第十九次会议决议公告 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）披露的《黑龙 江珍宝岛药业股份有限公司关于减少注册资本、取消监事会并修订<公司章程> 及相关公司治理制度的公告》（公告编号：临 2025-044 号），修订后的《黑龙江 珍宝岛药业股份有限公司章程》详见上海证券交易所网站 www.sse.com.cn。 特此公告。 黑龙江珍宝岛药业股份有限公司监事会 2025 年 6 月 5 日 1 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）第五届监事会第十九 次会议于 2025 年 6 月 4 日以现场方式在公司 4 号会议室召开。会议通知已于 2025 年 5 月 30 日以电子邮件方式送达至全体监事。本次会议应参会监事 3 名，实际 参会监事 3 名，会议由公司监事会主席兰培宝先生主持。会议的召集和召开符合 《中华人民共和国公司法》 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）第五届董事会第二十 三次会议于 2025 年 6 月 4 日以现场结合通讯的方式召开。会议通知已于 2025 年 5 月 30 日以电子邮件等方式送达至全体董事。本次会议应参会董事 5 名，实 际参会董事 5 名，会议由公司董事长方同华先生主持。会议的召集和召开符合《中 华人民共和国公司法》和《公司章程》等有关规定。会议审议并通过以下议案： 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-042 黑龙江珍宝岛药业股份有限公司 第五届董事会第二十三次会议决议公告 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）披露的《黑龙 江珍宝岛药业股份有限公司关于减少注册资本、取消监事会并修订<公司章程> 及相关公司治理制度的公告》（公告编号：临 2025-044 号）。 三、审议并通过了《关于提请召开公司 2024 年年度股东大会的议案》 公司定于 2025 年 6 月 25 日召开 2024 年年度股东大 ...

Core Viewpoint - The company, Zhenbao Island, faced criticism from the Shanghai Stock Exchange for failing to timely disclose a significant transaction that generated a net profit of approximately 420 million yuan, which accounted for 227% of its audited net profit for 2022 [1][2][3] Group 1: Transaction Details - The undisclosed transaction involved the sale of 100% equity of its subsidiary, Hulin Fangsheng Pharmaceutical Technology Co., which was sold for 425 million yuan to Heilongjiang Hehui Pharmaceutical Co. [2][3] - The transaction's profit exceeded the threshold requiring shareholder approval and timely disclosure, as it represented over 50% of the company's audited net profit for the previous year [2][3] Group 2: Regulatory Issues - This is not the first instance of Zhenbao Island facing issues related to information disclosure; the company has received warnings and criticisms from regulators multiple times in the past two years for similar violations [4] - In April 2024, the company was issued a warning by the Heilongjiang Securities Regulatory Bureau for failing to disclose a related party transaction involving 80 million yuan in non-operating fund occupation [4] Group 3: Financial Performance - Zhenbao Island reported revenues of 4.2 billion yuan, 3.1 billion yuan, and 2.7 billion yuan for the years 2022, 2023, and 2024 respectively, with a net profit of 753 million yuan in Q1 of the current year, down from 2.9 billion yuan in the same period last year [5] - The decline in Q1 performance was attributed to the postponement of the third batch of national traditional Chinese medicine procurement, which affected sales and profits [5]

Core Viewpoint - Zhenbaodao is accelerating the improvement of its traditional Chinese medicine industry chain layout through the acquisition of a 49% stake in Guizhou Shennong Valley, which will become a wholly-owned subsidiary of its subsidiary Bozhou Trading Center [1] Group 1: Acquisition Details - The acquisition amount is 490 million yuan, which includes the investment principal and interest from the fund during the investment period [1] - Guizhou Shennong Valley was established in August 2023 with a registered capital of 1 billion yuan [1] - As of March 31, 2025, Guizhou Shennong Valley has total assets of 1.062 billion yuan and net assets of 998 million yuan [1] Group 2: Financial Performance - In 2024, Zhenbaodao achieved revenue of 2.704 billion yuan, a year-on-year decrease of 13.84%, marking the lowest record in five years [2] - In the first quarter of 2025, the company reported a revenue decline of 58.03% to 469 million yuan and a net profit decline of 74.33% to 75.3 million yuan [2] - The decline in revenue and profit is attributed to the postponement of the third batch of national Chinese medicine procurement [2] Group 3: Product Development - On the same day as the acquisition announcement, Zhenbaodao received approval for clinical trials of its Fufang Qinlan Oral Liquid for children aged 4-12 [3] - The pediatric medication sector is experiencing significant policy benefits, and Fufang Qinlan Oral Liquid is positioned as a core product in Zhenbaodao's "anti-viral Chinese medicine matrix" [3] - The company’s total assets reached approximately 12.713 billion yuan by the end of 2024, with a year-on-year growth of 1.98% [3]

Group 1 - The core viewpoint of the articles highlights the positive operational developments of listed companies in the second quarter of 2025, showcasing advancements in various sectors such as semiconductors, robotics, new energy, and new materials [2][3] - Companies are actively sharing updates on project progress, new technologies, and orders, indicating a trend of industrial upgrades and strategic transformations [2][3] - High-growth sectors continue to exhibit strong growth momentum, while cyclical industries are seeking balance amid supply-demand adjustments [3] Group 2 - Chip companies are benefiting from the AI industry, with interconnect chip orders exceeding RMB 12.9 billion as of April 22, 2025, and expectations for significant growth in DDR5 memory interface chip demand [4] - Traditional cyclical industries like coal and chemicals are showing resilience through cost control and structural optimization, with companies like Guanghui Energy anticipating stabilization in coal prices due to various market factors [4][5] - Manufacturing companies are focusing on improving production efficiency and meeting customer demands, with firms like Xinqianglian and Guangxin Materials reporting strong order backlogs and plans for product launches [5] Group 3 - Many listed companies are already building momentum for annual revenue growth, particularly in emerging sectors like new energy and robotics, with plans for market expansion and quality enhancement through mergers and acquisitions [6] - Companies like Longmag Technology are localizing raw material supply to reduce production costs and enhance supply chain stability [6] - Hechuan Technology is actively developing humanoid robots and plans to launch new products in the second half of 2025 [6] Group 4 - The new merger regulations have made acquisitions a key strategy for A-share companies to optimize resource allocation, with firms like Chenhua Co. targeting investments in new materials and fine chemical agents [7] - Guoxing Optoelectronics is focusing on upstream and downstream opportunities in the LED and optical sensing sectors, while Zhenbaodao is exploring new industries through asset acquisitions [7] - Huichuan Technology is looking for overseas acquisition opportunities, concentrating on automation, digitalization, and intelligent sectors that align with its core business [7]

Core Viewpoint - The acquisition of a 49% stake in Guizhou Shennong Valley by Zhenbaodao for 490 million yuan is seen as a strategic move to enhance its presence in the traditional Chinese medicine industry in Guizhou, despite concerns over high debt levels and the target company's losses [1][2]. Financial Performance - In Q1 2025, Zhenbaodao's net profit attributable to the parent company plummeted by 74.33% to 75.29 million yuan, with negative cash flow from operating activities amounting to -267 million yuan, a 158% decrease year-on-year [2]. - The company's cash reserves decreased by 43% year-on-year to 781 million yuan, while interest-bearing liabilities reached 3.46 billion yuan, resulting in an asset-liability ratio of 35% [1][2]. Acquisition Details - The acquisition requires a payment of 490 million yuan, which would consume 62.7% of Zhenbaodao's cash reserves [1]. - Guizhou Shennong Valley reported revenue of 51.1 million yuan in 2024, with a net profit of only 162,800 yuan, and experienced a significant revenue drop to 197,200 yuan in Q1 2025, incurring a loss of 1.78 million yuan [2]. - The valuation of the 49% stake in Guizhou Shennong Valley at 490 million yuan corresponds to a static price-to-earnings ratio exceeding 3000 times, indicating a significant disparity between the estimated future cash flows and the transaction price [2].

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-041 黑龙江珍宝岛药业股份有限公司 关于全资子公司收购其控股子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）全资子公司亳州 中药材商品交易中心有限公司（以下简称"亳州交易中心"）拟收购其控股子公 司贵州神农谷健康产业发展有限公司（以下简称"贵州神农谷"）49%的股权。 收购完成后，贵州神农谷将成为亳州交易中心的全资子公司。 1、企业名称：贵州省农业农村现代化发展股权投资基金合伙企业（有限合 伙） 2、统一社会信用代码：91520115MAAKDYDC8Q 3、成立时间：2021 年 3 月 29 日 4、出资额：1,800,100 万元人民币 ● 本次投资金额为贵州省农业农村现代化发展股权投资基金合伙企业（有 限合伙）（以下简称"贵州农业发展基金"）投资本金 49,000 万元人民币加投 资期内基金监管户活期存款利息。 一、交易概述 公司全资子公司亳州交易中心持有控股子公司贵 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-040 黑龙江珍宝岛药业股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到国家药品 监督管理局颁发的《药物临床试验批准通知书》，现就相关情况公告如下： 一、药品的基本情况 药品名称：复方芩兰口服液 通知书编号：2025LP01436 受理号：CYZB2500437 药品注册标准编号：《中国药典》2020 年版一部 注册分类：补充申请 剂型：合剂 规格：每支装 10ml 生产企业：黑龙江珍宝岛药业股份有限公司、黑龙江羽迪药业有限责任公司 药品批准文号：国药准字 Z20026049 药品批准文号有效期：至 2030 年 06 月 20 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 3 月 13 日受理的复方芩兰口服液（CYZB2500437）临床试验申请符合药品注 册的有关要求，在进一步完善临床试验方案的基础上，同意本品开展用 ...